FibroGen Reports Third Quarter 2023 Financial Results

Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40.1 million, an increase of 155% year over year Roxadustat sNDA accepted in China for chemotherapy-induced anemia Robust roxadustat volume growth of 37% in ChinaStrong execution of cost reduction plan reaffirming cash runway into 2026 SAN FRANCI

Related Keywords

China ,United States ,Turkey ,South Africa ,Japan ,Russia ,American ,Meichiel Keenan ,David Delucia ,Society For Immunotherapy Of Cancer Annual Meeting ,Corporate Communications ,Nasdaq ,Fibrogen Inc ,Exchange Commission ,European Society For Medical Oncology Congress ,Astrazeneca ,Drug Administration ,Pancreatic Cancer Action Network Pancan Precision Promise ,China Health Authority ,American Society Of Nephrology ,Pancreatic Cancer Action Network ,Thane Wettig ,Chief Executive Officer ,Key Events ,Third Quarter ,Chief Executive ,New Drug Application ,European Society ,Medical Oncology Congress ,American Society ,Kidney Week ,Cancer Annual Meeting ,Fibrogen China ,Webcast Details ,Orphan Drug Designation ,Fast Track ,Supplemental New Drug Application ,China Health ,Independent States ,Middle East ,Annual Report ,Quarterly Report ,Consolidated Statements ,Months Ended September ,Investor Relations ,Fibrogen ,Nc ,Cost Reduction ,The Company ,